April 21st 2024
During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the correlation between spleen volume responses and survival outcomes for patients with myelofibrosis in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
More Hematologic Responses Seen With Interferon-Alpha Than Hydroxyurea in MPN Comparison
April 16th 2019In an analysis comparing real-life outcomes, interferon-a demonstrated more profound hematologic responses compared with hydroxyurea in select patients with myeloproliferative neoplasms. Additionally, molecular responses to therapy were limited to those patients who received IFN-a.
Read More
Study Finds Extended-Release Anagrelide Noninferior to Reference Product in ET
April 16th 2019A new phase III trial has demonstrated that a novel extended-release formulation of anagrelide (Thromboreductin) is noninferior to immediate-release anagrelide in reducing platelet counts in patients with essential thrombocythemia.
Read More
Diagnosis, risk stratification, and the management of patients with polycythemia vera and myelofibrosis have all been significantly improved by the inclusion of a greater understanding of the clinical and molecular characteristics of these 2 different myeloproliferative neoplasms, according to Abdulraheem Yacoub, MD.
Read More
VA Broadens Comprehensive Care by Providing Genomic Testing in Advanced Cancer
March 8th 2019Genomic testing could increasingly be utilized to guide treatment decisions for Veteran patients with cancer. Two recent announcements confirm an emerging focus from Veterans Affairs on genetic testing that provides more informed and tailored cancer care for US Veterans.
Read More
FDA Gives Fedratinib Priority Review Designation for Myelofibrosis
March 5th 2019The highly selective JAK2 inhibitor fedratinib has received a priority review designation by the FDA as a treatment for patients with myelofibrosis. The designation was granted based on findings from the phase III JAKARTA and phase II JAKARTA-2 trials.
Read More
Mesa Discusses Evolving Role of Interferon in MPN Treatment Paradigm
February 22nd 2019Ruben A. Mesa, MD, discusses the evolving role of interferon in the treatment of patients with MPNs, highlights recent treatment advances, and shares insight on the future of treatment for these patients.
Read More
Expert Underscores Importance of Gaining Better Understanding of Mutations in Myelofibrosis
February 8th 2019Angela G. Fleischman, MD, PhD, discusses a clinical trial at her institution investigating the JAK1 inhibitor itacitinib in patients with MF. She also highlights other recent advancements for patients with MF, as well as advancements in other MPNs such as ET and PV.
Read More
Investigators Identify Starting Dose of Ruxolitinib in MF Patients with Thrombocytopenia
February 2nd 2019A phase Ib dose-finding study has established the maximum safe starting dose of ruxolitinib to be 10 mg twice daily in treating myelofibrosis in patients with low initial platelet counts.
Read More